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DPSN axons mediate and maintain a variety of normal spinal functions. Unsurprisingly, DPSN tracts have been shown to
mediate functional recovery following SCI. KLF7 could contribute to CST axon plasticity after spinal cord injury. In the
present study, we assessed whether KLF7 could effectively promote DPSN axon regeneration and synapse formation
following SCI. An AAV-KLF7 construct was used to overexpress KLF7. In vitro, KLF7 and target proteins were
successfully elevated and axonal outgrowth was enhanced. In vivo, young adult C57BL/6 mice received a T10 contusion
followed by an AAV-KLF7 injection at the T7–9 levels above the lesion. Five weeks later, overexpression of KLF7 was
expressed in DPSN. KLF7 and KLF7 target genes (NGF, TrkA, GAP43, and P0) were detectably increased in the injured
spinal cord. Myelin sparring at the lesion site, DPSN axonal regeneration and synapse formation, muscle weight, motor
endplate morphology, and functional parameters were all additionally improved by KLF7 treatment. Our findings suggest
that KLF7 promotes DPSN axonal plasticity and the formation of synapses with motor neurons at the caudal spinal cord,
leading to improved functional recovery and further supporting the potential of AAV-KLF7 as a therapeutic agent for
spinal cord injury.
1. Introduction
The compromised ability of central nervous system neurons
to regenerate their axons after injury is a well-documented
deficit and a significant hindrance to post-SCI therapeutic
strategies. Due to a variety of microenvironmental and
endogenous molecular cues, axonal plasticity and synaptic
recovery after SCI remain suboptimal, even after endogenous
injury-repair mechanisms are considered. The sheer number
of genes that must be up- or downregulated to reinitiate axon
extension after injury presents a major challenge toward tar-
geting the intrinsic neuronal growth state. One possible solu-
tion is the manipulation of underlying transcription factors
(TFs) in injured neurons to drive the expression of down-
stream regeneration-associated genes (RAGs) [4]. A growing
number of TFs have been functionally linked to axon growth
in a variety of cell types. For example, neuroregulin 1 has
been recently demonstrated as a crucial regulator of Schwann
cell differentiation and remyelination in the injured spinal
cord and thus as an attractive candidate for enhanced endog-
enous repair strategies [5]. Another study in a model of
incomplete SCI reported that neurotrophic upregulation
demonstrated an injury-specific BDNF response including
regenerative sprouting and increased connectivity of injured
neurons with propriospinal interneurons [6]. Other promis-
ing targets include the PRG3 gene, which induces filopodia
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formation and axonal growth and has also been shown to
overcome a range of neurite growth inhibitors, though not
yet evaluated in SCI specifically [7].
KLF7 is a transcription factor that has been found to play
a role in cell fate specification of neuroectodermal and meso-
dermal cell lineages, regulating neuron markers and nerve
growth factors such as NGF and TrkA [8]. Studies from optic
nerve injury in zebrafish have also described KLF7 as a regu-
lator of axon outgrowth [9]. Moreover, overexpression of
KLF7 has demonstrated the ability to promote sprouting
and axon regeneration in the adult corticospinal tract
(CST) [10]. In peripheral nerve injury, KLF7 upregulation
strategies have supported that KLF7 promotes axonal
regeneration in injured nerves and that it acts as a growth-
promoting transcription factor in injured neurons [11].
Similarly, when combined with chondroitinase viral expres-
sion, KLF7 promoted the regenerative growth of CST axons
to the injury site in a model of spinal injury [12], though
singularly, KLF7 upregulation was not apparently sufficient
to induce axonal regeneration.
Descending propriospinal neurons (DPSNs) are particu-
larly important in locomotion. As such, in SCI, restoring or
maintaining the functional integrity of DSPNs and their
axons may be a crucial component of motor functional
recovery. T9 contusion models have reported up to a 23%
loss of long descending propriospinal tract neurons as
detected by retrograde labeling [13]. They are attractive can-
didates for SCI due to their demonstrated ability to form new
intraspinal circuits [14] and act as relays between cortical and
spinal targets after injury (Bareyre et al. 2004). For example,
in rat spinal cord hemisections, neurochemical stimulation
of propriospinal neurons enhanced locomotor-like activity
when coupled with brainstem activation [15], suggesting that
it plays a critical role in transmission of locomotor command
signals. Further, in a lamprey injury model, DPSNs have even
been suggested as indirect activators of spinal locomotor net-
works in the absence of axonal regeneration of injured neu-
rons [16]. This cell population becomes even more relevant
in light of the observation that propriospinal axonal regener-
ation is more easily achieved by therapeutic methods than
supraspinal regeneration [17]. Moreover, DPSNs appear to
be more reactive toward regenerative treatment [18, 19].
All things considered, the effectiveness of KLF7 upregula-
tion strategies after SCI has not yet been evaluated in the crit-
ical DPSNs. Thus, to assess whether KLF7 could effectively
promote DPSN axon plasticity and synapse formation, we
modeled SCI using T10 contusion in young adult mice and
examined KLF7 and KLF7 gene targets following the delivery
of AAV-KLF7 to the T7–9 levels above the injury site. DPSN
morphological and electrophysiological traits were evaluated
along with functional outcomes. We report that AAV-KLF7
overexpression upregulated KLF7 target genes NGF and
TrkA and enhanced neurite outgrowth in both spinal cord
neurons and DRG neurons in vitro. An AAV-KLF7 injection
into the T7–9 levels above the lesion was also found to
improve the electrophysiological and morphological charac-
teristics of DPSNs at the caudal spinal cord, consequently
improving functional parameters. These findings confirm
the therapeutic effectiveness of KLF7 overexpression in
axonal plasticity and synaptic plasticity in a motor-relevant
neuronal population, furthering the case for AAV-KLF7 as
a therapeutic agent in spinal cord injury.
2. Materials and Methods
2.1. Viral Vector Preparation. The AAV-GFP virus contained
both AAV serotype 2 capsid and expressed GFP. GFP expres-
sion which was expressed under the control of the cytomeg-
alovirus (CMV) immediate-early promoter (AAV2-GFP,
1.0× 1013 viral particles/ml; Vector BioLabs, Philadelphia,
USA) was used as a control. Mouse KLF7 was subcloned into
an AAV2 vector cassette under the control of the CMV
(AAV-m-KLF7; Vector BioLabs, Philadelphia, USA).
2.2. Rat E15 Primary Spinal Cord Neuron Culture. Sprague-
Dawley rat embryos (E15) were used for isolation of spinal
cord neurons according to a previously established protocol
[20]. Briefly, rat E15 spinal cords were harvested and placed
in L15 medium. The dissociated cells were washed with and
triturated in 10% heat-inactivated fetal bovine serum (FBS),
5% heat-inactivated horse serum (HS), and 2mM glutamine
DMEM (all culture reagents were obtained from Gibco,
USA) and cultured in a 10 cm plate for 30min at 37°C to
eliminate glial cells and fibroblasts. Neurons were next plated
onto poly-L-lysine-coated 48-well plates and incubated in a
humidified atmosphere containing 5% CO2 at 37
°C with
10% FBS+5% HS+2mM glutamine DMEM for 16 hours.
Medium was then replaced with serum-free neurobasal
medium supplemented with 2% B27 (Gibco), 1% N2 (Gibco),
and 2mM glutamine. All experiments were performed
between 7 and 10 days of plating.
2.3. AAV-KLF7 Transduction in Spinal Cord Neurons In
Vitro. Spinal cord neurons were seeded on 6-well plates
(5× 105 cells/well) and grown to over 90% confluence.
After confluence was reached, cells were pretreated with
4–6μg/ml polybrene (Sigma, USA) for 30–60min followed
by infection with AAV2-GFP (final concentration 6.5× 109
viral particles/ml) and AAV2-KLF7 (6.5× 109 viral parti-
cles/ml) at a multiplicity of infection (13,000 moi). Four days
after virus introduction, infection media were replaced with
fresh media and cells were collected for immunostaining,
Western blot, and transplantation experiments. For cells
undergoing immunostaining procedures, cultures were fixed
and examined using a mouse monoclonal anti-β-III-tubulin
antibody (1 : 200; Sigma, St. Louis, USA), KLF7 (1 : 200;
Novus Biologicals, Colorado, USA), and DAPI (1 : 200;
Sigma, St. Louis, USA) to identify neurite outgrowth and
confirm KLF7 expression.
2.4. Dynamic Neurite Outgrowth In Vitro. Spinal cord neur-
ites were seeded at 2× 105 per well in 48-well plates four days
after viral infection. The dynamic outgrowth of neurites was
recorded using the IncuCyte ZOOM Kinetic Imaging System
(Essen BioScience, USA) every 4 hours for 4 days after viral
treatment. Three views from each well were recorded and
data were analyzed by IncuCyte ZOOM software according
to a previous methodology [21] (n = 50 neurons/group).
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2.5. DRG Explant Cultures. Lumbar dorsal root ganglia
(DRG) were extracted from Sprague-Dawley rat embryos at
E15 and placed in 12-well dishes. 600μl of conditioned
medium collected from confluent AAV-GFP or AAV-KLF7
cultures (collected at various 24h intervals) or medium sup-
plemented with BDNF (730 ng/ml) and NT-3 (730 ng/ml)
was added to the wells for 3 d at 37°C in 5% CO2. DRG
explant cultures were subsequently fixed and immunostained
using mouse monoclonal anti-β-III-tubulin antibody (1 : 200;
Sigma, St. Louis, USA). Neurite outgrowth was evaluated by
Sholl analysis according to a previous study [22]. Briefly, we
used grids of concentric circles 10mm apart and counted
the average neurite length and neurite length in angle bins.
2.6. Animals. Thirty-six C57BL/6 mice (male = 18,
female = 18, eight weeks old, weight range 18–22 g) were
obtained from the Experimental Animal Center of China
Medical University (Certification number SCXK Liao 2003-
0009). Animals were housed with three or four mice per cage
and received standard food and water ad libitum. All experi-
mental protocols used in this study were reviewed and
approved by the Animal Care and Use Committee of China
Medical University.
2.7. In Vivo Experimental Groups and Surgical Procedures.
Mice were randomly divided into three groups—group I:
sham group (n = 12); group II: SCI +AAV-GFP group, con-
tusive SCI and injection with AAV2-GFP control vector
(n = 12); and group III: SCI +AAV-KLF7 group, contusive
SCI and injection with AAV2-KLF7 (n = 12) (Figure 1).
Mice were anesthetized with a xylazine (10mg/kg) and
ketamine (100mg/kg) cocktail delivered by intraperitoneal
injection. A contusive SCI was performed after mice were
fully anesthetized at the T10 level using the Louisville Injury
System Apparatus (LISA) [23]. Viral injections occurred 1
week after SCI; mice in the SCI +AAV-GFP group and SCI
+AAV-KLF7 group received a 0.5mm displacement contu-
sion at a velocity of 1.0m/s while sham animals received
laminectomy only. Microinjections of KLF7 were then deliv-
ered into the T8-9 level of the mouse spinal cord according to
a previously described method [24]. Briefly, a beveled glass
micropipette (external diameter, 10–20μm) was loaded with
2μl of AAV-KLF7 (6.5× 109 viral particles/ml) or AAV-GFP
(6.5× 109 viral particles/ml) and bilaterally injected into the
spinal cord (2μl/side) at 0.6mm lateral to the midline and
1.5mm ventral to the dorsal surface of the cord for 10min.
The overlying musculature was closed using sutures, and
the skin was closed using wound clips after which animals
were treated with Marcaine at the incision site.
Mice were placed on a heating blanket and maintained at
37°C until completely recovered from anesthesia. All mice
were housed and fed routinely and monitored closely for
changes in their general conditions and locomotor capacity.
2.8. Histological Assessments. Five weeks after contusion
injury, animals were perfused and the cord segments were
dissected, embedded, and sectioned in 20μm increments
according to our previously established protocol [24]. A set
of serial cross sections of the spinal cord was stained for mye-
lin using Luxol fast blue and was counterstained with cresyl
violet-eosin. Lesion areas were outlined and quantified using
an Olympus BX60 microscope equipped with a Neurolucida
system (MicroBrightField, Colchester, VT). Areas of demye-
lination were quantified using ImageJ (NIH imaging soft-
ware, Bethesda, USA).
2.9. Immunohistochemistry. Before sectioning, the cords were
segmented using the dorsal roots as landmarks as follows:
serial, 25μm thick sections were cut from the rostral spinal
cord (T7–9 segment), epicenter (the injured T10 segment),
and caudal spinal cord (L2–L5 lumbar segment) using a
cryostat. The images of every 5th section were quantified.
Sections were carefully mounted onto Superfrost Plus
slides (Menzel-Glaser, Braunschweig, Germany) and proc-
essed for immunohistochemical detection. Tissues were
stained with antibodies against KLF7 (1 : 200; Novus Biolog-
icals, Colorado, USA), peripheral myelin or P0 (1 : 200;
Sigma-Aldrich, Missouri, USA), GFAP to identify astrocytes
(1 : 200; Sigma-Aldrich), BDA to identify astrocytes (1 : 200;
Sigma-Aldrich), SYP to identify presynaptic components
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Figure 1: Experimental timeline. SCI: spinal cord injury; AAV: adeno-associated virus; CTB: cholera toxin B; FG: Fluoro-Gold;
tcMMEP: transcranial magnetic motor-evoked potentials; BDA: biotinylated dextran amine; BMS: Basso Mouse Scale; TEM: transmission
electron microscope.
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(1 : 500; Sigma-Aldrich), CC1 to identify oligodendrocytes
(1 : 200; Sigma-Aldrich), and NG2 to identify oligodendro-
cyte precursors (1 : 200; Sigma-Aldrich). The immunoreac-
tivity signals were visualized by goat anti-rabbit IgG
(FITC), anti-mouse IgG (TRITC), and anti-donkey IgG
(CY5) (1 : 200; Jackson ImmunoResearch Laboratories,
Pennsylvania, USA), and images were obtained with an
Olympus BX-60 epifluorescent microscope and Neurolucida
software (MicroBrightField). The cross-sectional area was
measured using an Olympus BX60 microscope at a 20x view
field (27,000μm2), and pixel intensity was measured on
images with a uniform exposure setting and analyzed using
ImageJ (NIH, Bethesda, MD). Five sections were analyzed
per sample. No image modification was performed prior to
measurements. Multipanel figures were assembled in Adobe
Photoshop CS6 software (Adobe Systems, San Jose, CA).
All immunohistochemistry image quantifications were
performed blind. The numbers of retrogradely labeled neu-
rons were counted from every eighth section in each spinal
block through the microscope eyepiece by an experimenter
blinded to the experimental condition. Only neurons with a
nucleus and proximal dendritic processes that were visible
upon focusing through the thickness of the section were
included in the cell counts. Cell counts are reported from
each spinal block as group means. To analyze propriospinal
axon sprouting and synapse formation, contacts onto motor
neurons throughout the lumbar level of the sectioned spinal
cord were used for quantification. Propriospinal axon
sprouting was in some cases defined as projections or
branches of axons, cholera toxin B-labeled motoneurons, or
SYP-labeled synapses in the ventral gray of the L2–L5 spinal
cord using triple immunohistochemical staining. Axonal
sprouting was quantified by counting the pixel intensity of
BDA-positive axonal sprouts surrounding CTB-positive
motoneurons in the ventral gray (VIII–IX) using ImageJ
[25]. To analyze the synapse contacts onto motor neurons,
cholera toxin B-labeled motoneurons were automatically
selected and a constant threshold was used to segment and
obtain an estimated average density for each label using
ImageJ software [26]. Detection of the immunoreactivity
was performed using a fixed threshold for every staining
(the motoneurons and dendrites were labeled with CTB
and synapses were labeled with SYP). Immunoreactivity
was evaluated in a circular perimeter of 5μm width sur-
rounding each motoneuron. This 5μm width perimeter cov-
ered the synaptic area surrounding motoneurons, limiting
overlap with the synapses of neighboring motoneurons.
2.10. Electron Microscopy. Spinal cord tissue from the ventral
white matter was obtained from a normal uninjured spinal
cord (sham group) as well as from the lesion around the epi-
center in SCI +AAV-GFP and SCI+AAV-KLF7 groups;
these segments were fixed overnight in the solution contain-
ing 2% glutaraldehyde and 5% sucrose in 0.1M sodium caco-
dylate buffer (pH7.4). The following day, 1 hr incubation was
performed in 1% osmium tetroxide in the same buffer. The
tissue was then embedded in Spurr’s epoxy resin and cured
at 70°C. Ultrathin sections (70–90 nm) were collected on
copper mesh grids (600 bars per inch) and subsequently
counterstained with 4% uranyl acetate in 50% ethanol and
Reynolds’ lead citrate. Finally, sections were examined using
a Philips CM10 electron microscope. For each mouse, micro-
graphs representing different grid squares of a single section
were randomly selected for quantitative analysis. The total
number of axons was obtained with Stereo Investigator soft-
ware (MicroBrightField). Myelinated axons were identified
by their characteristic myelin sheaths relative to the diameter
of the axons. Unmyelinated axons were identified by the
absence of the characteristic myelin sheaths. Myelin ratio
(MR) was used to detect whether AAV-KLF7 could promote
axonal myelination around the lesion site following SCI as
previously described [27].
We measured the axonal diameter (d) as the shortest
distance across the center of axons, avoiding the myelin
sheath thickness. The axonal diameter plus the total myelin
sheath thickness on both sides was defined as fiber diameter
(D). The myelin ratio (MR) was calculated using the D/d
ratio. For each mouse, micrographs representing different
grid squares of a single section were randomly selected for
quantitative analysis. More than 50 randomly chosen fibers
per animal were analyzed, using the MIAS image analysis
system by two blinded researchers.
2.11. Anterograde and Retrograde Tracing. On day 28 after
spinal cord injury, after animals were anesthetized, bilateral
and stereotaxic injections of biotinylated dextran amine
(BDA; 10%, 1μl/site; Molecular Probes) were made into the
intermediate gray matter of the T7-T8 cord at distances of
3–6mm rostral to the contusion (for BDA, 1 injection/site/
mm) as described in a previously published work (n=8/each
group) [18].
BDA staining was subsequently performed. Specifically,
slides were dried at 38°C for 1 h and washed twice for
10min in 50mM Tris-buffered saline (TBS, pH7.4), followed
by two 45min washes with TBS containing 0.5% Triton X-
100. Slides were then incubated overnight with an ExtrAvi-
din®-FITC buffered aqueous solution or ExtrAvidin-TRITC
buffered aqueous solution (1 : 200; Sigma, St. Louis, USA)
according to the manufacturer’s instructions. The reaction
was monitored closely and stopped by extensive washing
in water.
For the retrograde tracing, both sides of animal sciatic
nerves were exposed and 1-2μl of 2% solution of Alexa
Fluor-labeled (594) cholera toxin B (Invitrogen, USA) was
injected using a Hamilton syringe with a 30-gauge needle.
CTB retrograde labeling targeted the lumbar motor neurons
(n = 8/each group).
2.12. FG Retrograde Labeling of DPSNs. Before one-week
surgery, for Fluoro-Gold (FG) retrograde labeling, 2% FG
(Sigma39,286, Sigma-Aldrich, St. Louis, MO) was bilaterally
injected into the intermediate gray matter (laminae V–VII)
of the L2 spinal cord (0.75μl/side) using a stereotaxic appara-
tus [18]. Analysis of the DPSN was restricted to the T6–T10
spinal cord segments, with axonal projections to the L2 spinal
cord segment. Additionally, only neurons whose somata
were located in the intermediate gray matter (Rexed lamina
VII) were included for analysis.
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2.13. Western Blotting and PCR. Spinal cord neuron cell sam-
ples were homogenized and processed for Western blot anal-
ysis 4 d after viral transfection with evaluated AAV-KLF7
that significantly increased the expression of KLF7 and target
proteins in vitro (6 wells/each group). To evaluate changes in
KLF7 expression at the thoracic level in vivo, samples col-
lected at different time points (1 day and 1, 2, 3, and 4 weeks
after SCI) were homogenized for total protein extraction
(n = 3). To evaluate the expression of KLF7 target proteins at
the thoracic level, the spinal cord was harvested five weeks
after SCI (n = 6). The spinal cord was dissected and washed
in saline. After the dura mater was carefully removed,
the tissue was snap-frozen on dry ice. Next, protein isolation
was performed and protein samples (20μg) were electropho-
resed on SDS-polyacrylamide gels and transferred to polyvi-
nylidene difluoride membranes (Millipore, Bedford, MA).
The blots were incubated with primary antibodies against
KLF7 (1 : 500; Novus Biologicals, Colorado, USA), NGF
(1 : 500; Sigma, USA), TrkA (1 : 1000; Sigma, USA), GAP43
(1 : 1000; Sigma-Aldrich, Missouri, USA), and P0 (1 : 1000;
Sigma, USA) overnight followed by incubation with an
HRP-conjugated secondary antibody for 1 h at room temper-
ature (1 : 5000). Blots were visualized using the enhanced
chemiluminescence (ECL) plus the detection system (GE
Healthcare, Little Chalfont, UK); the exact exposure time
was determined as 1 minute and used uniformly across all
proteins. Experiments were repeated three times under the
same condition; for determination of individual band differ-
ences, the intensity of each band was calculated from Image-
Quant and the ratio of the target protein to the housekeeping
protein GAPDH was generated. Data were expressed as
mean± standard deviation (SD) of the mean. Error bar is
SD (standard deviation). Using one-way ANOVA with
Tukey’s post hoc test to determine statistical significances,
experiments were repeated three times under the same
conditions for a representative average.
Using a similar dissection method, total RNA was
extracted using the RNeasy Kit (Qiagen, California, USA)
according to the manufacturer’s instructions. KLF7, NGF,
and TrkA cDNA was next amplified from 2.5 g total RNA
using the SuperScript II First-Strand Synthesis RT-PCR kit
(Life Technologies) and the following parameters: KLF7
reverse transcription at 42°C for 15 minutes using primers
5-TTTCCTGGCAGTCATCTGCAC-3 and 5-GGGTCTGT
TTGTTTGTCAGTCTGTC-3, 219 bp; NGF primers 5-CAT
AGCGTAATGTCCATGTTGTTCT-3 and 5-CTTCTCATC
TGTTGTCAACGC-3, 395 bp; and TrkA primers 5-ATGG
ACAACCCTTTCGAGTTCAAC-3 and 5-GACCCCAAAA
GGTGTTTCGTCC-3, 412 bp. Finally, about 100ng of puri-
fied genomic DNA was amplified for 35 to 50 cycles using
the following parameters: 94°C for 2min, 94°C for 1min,
59°C for 1min, and 72°C for 2min, and genotyping was
performed as previously described [28].
2.14. Muscle Weight and Motor Endplate Morphology. To
assess potential atrophic changes in the target musculature
after SCI, the right TA muscles were removed immediately
after perfusion (5 weeks after injury) and weighed. Muscles
were then postfixed overnight in the same fixative as was
used for perfusion and then transferred to sucrose phosphate
buffer (10% w/v, pH7.4) solution for one week. Muscle
tissues were then rinsed in distilled water, blocked into
proximal and distal segments, and flash-frozen in 2-
methylbutane. Muscle segments were then sectioned
(45μm) longitudinally (for examination of the motor end-
plate area and density) on a cryostat. Muscle fibers were
assessed after staining with Milligan’s trichrome stain.
Motor endplate size and density were assessed after stain-
ing for acetylcholinesterase using the Roots-Karnovsky
method [29].
2.15. Measurements of Axonal Conduction.Nerve conduction
was assessed using transcranial magnetic motor-evoked
potentials (tcMMEP) as an in vivo electrophysiological mea-
sure of motor pathway function according to our previously
outlined method [30]. The tcMMEP responses were elicited
by activation of subcortical structures using an electromag-
netic coil placed over the cranium. Action potentials
descending in the ventral spinal cord and synapsing onto
motoneuron pools were used to record output signals from
both gastrocnemius muscles [31, 32].
2.16. Behavioral and Locomotor Assessments. The Basso
Mouse Scale (BMS) locomotor test was performed 1, 2, 3, 4,
and 5 weeks after AAV-KLF7 injections and contusive SCI
by 2 independent observers lacking knowledge of the exper-
imental groups according to a method published previously
[33]. During evaluation, animals were allowed to walk freely
on an open-field surface for 4min sessions as observers
scored the locomotor capacity of the animals. The BMS was
observed by two observers who were blinded to the allocation
of the animals. Videos were recorded for further analysis in
case of divergence in the BMS scores assigned by the
observers. If there was a divergence, the evaluators discussed
the case until they reached a consensus.
Additionally, animals were placed to walk on a 1m long
horizontal runway of metal grid bars elevated 30 cm from
the ground. A defined 10-bar sector was chosen for analysis.
To prevent habituation to a fixed bar distance, the bars in this
sector were irregularly placed (1–4 cm spacing) and were
changed after every testing session. Analysis of grid walk
included counting the number of errors in foot placing
occurring during each bar sector trial. Each animal had to
cross this sector three times. If the animal did not show hind
limb weight support, it made two errors per bar, resulting in a
total of 20 errors [34].
2.17. Statistical Analysis. The BMS performed a two-way
repeated-measures ANOVA to compare the three groups.
No normality tests were performed because the BMS is a
nonlinear scale. Post hoc analysis at individual time point
was performed with Tukey’s test.
Statistical analysis was performed using SPSS software
(version 13.0; SPSS, Illinois, USA). All values were expressed
as the mean with the corresponding standard deviation. Sam-
ple sizes were determined using statistical software to calcu-
late the minimum number of animals required for sufficient
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statistical power for each assay. All reported sample sizes are
above the minimum calculated requirement.
The Kolmogorov-Smirnov test was used to distinguish
between parametric or nonparametric data. All parametric
values were analyzed using two-tailed Student’s t-test or
one-way ANOVA and Tukey’s post hoc test. Analyses were
carried out with GraphPad Prism 6.0 software. A P value of
<0.05 was considered statistically significant.
3. Results
3.1. Efficacy of AAV2-KLF7 Gene Transfer to Spinal Cord
Neurons In Vitro. To verify the successful transduction of
KLF7 with the AAV2 vector, we first examined AAV2-
GFP-infected spinal cord neurons in vitro (Figure 2(a)).
The AAV2-GFP transfection of spinal cord neurons was
successful, with a transfection efficiency of 84.70± 5.57%
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Figure 2: Efficacy of AAV2-KLF7 gene transfer to spinal cord neurons in vitro. (a) AAV-GFP-infected cultured spinal cord neurons. Scale
bars: 50μm. (b) Quantitative analysis of AAV2-GFP infection rate. Representative immunohistochemical staining of KLF7 (green) and β-
III-tubulin (labeling neurite and dendrite outgrowth, red) with nuclear staining (DAPI, blue) in cultured spinal cord neurons in the AAV-
GFP (c) and AAV-KLF7 groups (d). Block shows the KLF7 colabeling of nuclei and neurite outgrowth. Quantitative analyses of the KLF7
relative density (e) and neurite length/neuron (f) in the two groups. n = 6 wells/group. Student’s t-tests, ∗∗∗P < 0 001. Scale bars: 200 μm.
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(Figure 2(b)). Next, the transfection efficiency of AAV2-
KLF7 was similarly evaluated in spinal cord neurons using
immunohistochemical staining of KLF7 (Figures 2(c) and
2(d)). We found that the expression of KLF7 was significantly
increased following AAV2-KLF7 (1306± 275.1) transduction
compared to that of the AAV-GFP (160.7± 68.73)-receiving
group (t10 = 9.888, P < 0 001) (Figure 2(e)). Additionally,
β-III-tubulin immunolabeling was used to evaluate whether
induction of KLF7 promoted neurite outgrowth of spinal
cord neurons. A significant increase was detected in neurite
length average of the AAV-KLF7 group (697.6± 441.7μm/
neuron) compared to AAV-GFP-transfected controls (322.8
± 213.3μm/neuron) (t70 = 4.585, P < 0 001) (Figure 2(f)).
3.2. AAV-KLF7 Significantly Increased the Expression of
KLF7, NGF, and TrkA in Spinal Cord Neurons In Vitro. Four
days after in vitro transfection with the AAV-KLF7, KLF7
protein (AAV2-KLF7, 0.372± 0.041; AAV-GFP, 0.126±
0.019; and control, 0.124± 0.021; F2, 15 = 70.63, P < 0 001)
and mRNA (AAV2-KLF7, 1.218± 0.078; AAV-GFP, 0.925±
0.109; and control, 0.918± 0.086; F2, 15 = 13.68, P < 0 05)
expression was found significantly increased compared to
that of AAV-GFP controls (Figures 3(b) and 3(f)). Simi-
larly, NGF protein (AAV2-KLF7, 1.181± 0.174; AAV-
GFP, 0.454± 0.058; and control, 0.451± 0.089; F2, 15 = 37.91,
P < 0 001) and mRNA (AAV2-KLF7, 1.278± 0.147; AAV-
GFP, 0.912± 0.076; and control, 0.888± 0.136; F2, 15 = 9.293,
P < 0 05) and TrkA protein (AAV2-KLF7, 0.556± 0.038;
AAV-GFP, 0.377± 0.051; and control, 0.357± 0.065; F2, 15 =
12.79, P < 0 05) and mRNA (AAV2-KLF7, 1.310± 0.091;
AAV-GFP, 0.823± 0.073; and control, 0.741± 0.151;
F2, 15 = 23.20, P < 0 05) expression in the AAV-KLF7 group
was considerably higher than that in control cells and
AAV-GFP-infected cells (Figures 3(c), 3(d), 3(g), and 3(h)).
However, no difference in protein or mRNA expression of
KLF7, NGF, or TrkA was found between the control and
AAV-GFP group. As NGF and TrkA are considered down-
stream targets of KLF7, these results suggested a successful
and functional induction of KLF7 by AAV2 infection in
spinal cord neurons in vitro. Due to group-specific increases
in KLF7 and its targets, it is unlikely that increases can be
attributed to intrinsic or compensatory phenomena.
3.3. KLF7 Overexpression Promotes Neurite Outgrowth of
Spinal Cord Neurons and DRG Explants In Vitro. To test
the effect of AAV-KLF7 on neurite outgrowth of spinal
cord neurons in real time, we used time-lapse imaging of
spinal cord neurons using the IncuCyte ZOOM Kinetic
Imaging System (Figures 4(a) and 4(b)). Results showed
that compared to those of the AAV-GFP group, AAV-
KLF7 neurons displayed dramatic increases in neurite
length (3 d: AAV-GFP, 6.211± 1.490μm/neuron; AAV-
KLF7, 9.723± 2.125μm/neuron; t98 = 4.236, P < 0 01; 4 d:
AAV-GFP, 9.234± 2.575μm/neuron; AAV-KLF7, 14.162±
2.731μm/neuron; t98 = 2.993, P < 0 01 (Figure 4(c))) and
neurite branching (3 d: AAV-GFP, 13.365± 2.490/neuron;
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Figure 3: AAV-KLF7 significantly increased the expression of KLF7 and target proteins in vitro. (a) Representative Western blot analysis of
KLF7, NGF, and TrkA expression in the cultured spinal cord neurons of the three groups is shown at 4 days in vitro (6 wells/each group). The
graphs represent the relative density of KLF7 (b), NGF (c), and TrkA (d) protein. (e) Representative RT-PCR analysis of KLF7, NGF, and
TrkA expression in the cultured spinal cord neurons of the three groups is shown at 4 days in vitro (n = 6). The graphs represent the
relative density of KLF7 (f), NGF (g), and TrkA (h) mRNA. Error bars denote SD. ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001. NS: not
significant. One-way ANOVA, Tukey’s post hoc test.
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Figure 4: Continued.
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AAV-KLF7, 18.736± 2.121/neuron; t98 = 7.934, P < 0 001;
4 d: AAV-GFP, 14.417± 2.570/neuron; AAV-KLF7, 20.110±
2.731/neuron; t98 = 12.58, P < 0 001 (Figure 4(d))) of spinal
cord neurons 3-4 days after viral transfection.
Next, we evaluated the effect of KLF7 on neurite out-
growth of DRG explants using the same imaging techniques
(Figure 4(e)). Sholl analysis showed that the average neurite
length in the AAV-KLF7 group (451.70± 54.23μm) was
significantly higher than the average neurite length in the
AAV-GFP group (257.1± 49.95μm) (t22 = 7 921, P < 0 001)
(Figure 4(f)). The AAV-KLF7 showed the greatest neurite
length in 0–60° (512.8± 117.3 versus 297.8± 62.1μm,
P < 0 05), 180–240° (530.1± 94.7 versus 228.5± 36.9μm,
P < 0 05), 240–300° (522.3± 102.1 versus 242.3± 66.2μm,
P < 0 05), and 300–360° (469.2± 106.6 versus 246.9±
49.7μm, P < 0 05) angle bins compared with the AAV-GFP
(Figure 4(g)). Collectively, these results support that KLF7
overexpression plays an important role in promoting neurite
outgrowth in vitro.
3.4. KLF7 Expression Is Dynamically Altered following SCI.
The expression changes in KLF7 following SCI were con-
firmed by Western blot protein analysis (Figure 5(a)). KLF7
protein levels were initially low in baseline, uninjured spinal
cord tissue. The expression of KLF7 in the thoracic segments
of the spinal cord was induced by 1 day post-SCI, peaking
around 1-2 weeks postinjury and returning to baseline levels
by 3-4 weeks (baseline: 0.015± 0.007; 1 d: 0.390± 0.021;
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Figure 5: KLF7 expression is dynamically altered following SCI. (a)Western blot analysis revealed the endogenous change in KLF7 expression
in the thoracic spinal cord injury tissue after SCI. (b) Graphs represent the KLF7 relative density of the bands normalized to GAPDH across
different time points. n = 6, error bars denote SD. ∗P < 0 05, ∗∗∗P < 0 001 versus the baseline. One-way ANOVA, Tukey’s post hoc test.
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Figure 4: AAV-KLF7 promotes neurites outgrowth in vitro. Time-lapse imaging of spinal cord neuron axonal outgrowth in AAV-GFP (a)
and AAV-KLF7 (b) groups on 0, 3, and 4 days (IncuCyte ZOOM Kinetic Imaging System) in vitro. Data represent neurite length/neuron
(c) and neurite branch points/neuron (d) (n = 50 neurons/group). (e) Representative immunostaining of DRG explants in each group;
neurite outgrowth was labeled with β-III-tubulin (green). A comparison of the average length (f) and total of neurite length per neuron
within different angle bins (g) by Sholl analysis (n = 6/group). Error bars denote SD. ∗∗∗P < 0 001 versus the AAV-GFP control group.
Student’s t-tests. Scale bars: 50 μm or 100μm.
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1w: 0.420± 0.030; 2w: 0.393± 0.015; 3w: 0.126± 0.047; and
4w: 0.021± 0.008; F5, 24 = 20.00, P < 0 001) (Figure 5(b)).
The intrinsic injury response of the KLF7 protein supports
a role for KLF7 in endogenous injury repair after SCI
modeling in vivo.
3.5. AAV-KLF7 Significantly Increases the Expression of
KLF7 and Its Downstream Targets and Mitigates Injury-
Related Loss of the Myelination Protein following SCI. To
verify the successful delivery of AAV-KLF7 to the injured
tissue, KLF7 expression was examined using Western blot
protein analysis in thoracic segments of spinal cord tissues
harvested 5 weeks postinjury (Figure 6(a)). In the sham
(0.097± 0.023) and SCI+AAV-GFP groups (0.093± 0.026),
only a small amount of KLF7 was detected. Meanwhile, ani-
mals receiving the AAV-KLF7 treatment (0.546± 0.138)
demonstrated an increased amount of KLF7 protein expres-
sion comparatively (F2, 15 = 29.96, P < 0 001) (Figure 6(b)).
To test the effect of AAV-KLF7 on the expression of
KLF7 target genes in vivo, we examined the expression of
NGF and TrkA, the axon regeneration marker GAP43, and
the myelinated axonmarker P0 in thoracic spinal cord tissues
(Figure 6(a)). The results demonstrated that injury upregu-
lated the examined KLF7 protein targets and the axonal
regeneration marker GAP43, after which AAV-KLF7-
treated animals demonstrated higher expression in the tho-
racic segments of the injured spinal compared to AAV-GFP
controls (Figure 6). Specifically, the NGF, TrkA, and
GAP43 expression in the SCI +AAV-KLF7 group was higher
than that in the SCI +AAV-GFP group (NGF: SCI +AAV-
KLF7, 0.895± 0.064; SCI +AAV-GFP, 0.561± 0.055; and
sham, 0.394± 0.047; F2, 15 = 61.25, P < 0 001; TrkA: SCI +
AAV-KLF7, 0.703± 0.071; SCI +AAV-GFP, 0.500± 0.040;
and sham, 0.348± 0.054; F2, 15 = 29.20, P < 0 001; and
GAP43: SCI +AAV-KLF7, 0.950± 0.110; SCI +AAV-GFP,
0.732± 0.048; and sham, 0.513± 0.055; F2, 15 = 24.30,
P < 0 01) (Figures 6(c), 6(d), and 6(e)). Additionally, the
myelin maker P0 was drastically decreased after injury, likely
due to demyelination and degeneration occurring after SCI.
Treatment with AAV-KLF7, however, was able to signifi-
cantly increase postinjury abundance of the P0 protein com-
pared to AAV-GFP treatment (Figure 6(f); SCI +AAV-KLF7,
0.782± 0.063; SCI +AAV-GFP, 0.425± 0.077; and sham,
2.579± 0.216; F2, 15 = 280.2, P < 0 001). These results corrob-
orate that the AAV-KFL7 upregulation technique was lasting
and capable of impacting the downstream targets of the
transcription factor including NGF-, TrkA-, and GAP43-
mediated signaling cascades which have been shown to play
roles in axon plasticity and remyelination. Additionally,
treatment with KLF7 overexpression mitigated the injury-
related decrease in the myelin protein P0.
3.6. AAV-KLF7 Treatment Improved Myelin Sparing
following SCI. To further assess the role of AAV-KLF7
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Figure 6: AAV-KLF7 significantly increased the expression of KLF7 and target proteins NGF, TrkA, GAP43, and P0 following SCI.
(a) Representative Western blot analyses of KLF7, NGF, TrkA, GAP43, and P0 expression in thoracic spinal cord section tissues
following SCI across three groups. The graphs for the analyses represent the relative density of KLF7 (b), NGF (c), TrkA (d), GAP43 (e),
and P0 (f). n = 6 mice/group. Error bars denote SD. ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001. NS: not significant. One-way ANOVA,
Tukey’s post hoc test.
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overexpression on myelination after injury and to examine
the effects of the treatment on pathological features, the
lesion area, lesion volume, and tissue sparing at the site of
T10 contusion injury were evaluated by cresyl echt violet
staining 5 weeks after contusive SCI. Results indicated that
AAV-KLF7 treatment had no effect on the lesion area (SCI
+AAV-KLF7, 57.78± 10.81%; SCI +AAV-GFP, 62.15
± 9.68%; t10 = 0.737, P > 0 05) nor on the lesion volume
(SCI +AAV-KLF7, 17.50± 2.44%; SCI +AAV-GFP, 19.14
± 3.43%; t10 = 0.869, P > 0 05) (Figures 7(a), 7(c), and 7(d))
compared to the AAV-GFP treatment following SCI. How-
ever, Luxol fast blue staining showed that AAV-KLF7 treat-
ment (28.83± 2.44%) increased the percent of myelin
sparing compared to the AAV-GFP treatment (23.92
± 3.85%) (t10 = 2.636, P < 0 05) (Figures 7(b) and 7(e)).
3.7. AAV-KLF7 Significantly Infects DPSNs at T7 and T9
Levels after SCI as Detected by FG Retrograde Labeling. FG
retrograde labeling of DPSNs was examined in Rexed lam-
ina VII at T7–9 levels above the spinal cord lesion by
immunofluorescence (Figures 8(a) and 8(b)). The results
showed no difference in the number of FG retrograde-
labeled neurons between the two groups (SCI +AAV-KLF7,
1003± 145.9; SCI +AAV-GFP, 887.7± 166.3; t10 = 1.277,
P > 0 05) (Figure 8(d)). However, we found that KLF7
expression and thus the percentage of FG/KLF7 double-
labeled neurons in the population were higher in the
SCI+AAV-KLF7 group compared to the SCI+AAV-GFP
group (KLF7: SCI+AAV-KLF7, 2971±701.1; SCI+AAV-
GFP, 195.1±101.5; t10 = 9 598, P < 0 001; percentage of FG/
KLF7 neurons: SCI+AAV-KLF7, 90.75±3.84%; SCI+AAV-
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Figure 7: Histological comparison of AAV-KLF7- or AAV-GFP-treated groups five weeks after contusive SCI. Cresyl violet-eosin (a)
and Luxol fast blue staining (b) in each group showed the level of SCI-induced tissue damage and loss of myelin. Quantitative
analyses of the lesion area (c), lesion volume (d), and myelin sparing (e) (n = 6 mice/group). Error bars show SD. Student’s t-tests,
∗P < 0 05. Scale bars: 300μm.
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GFP, 3.11±1.54%; t10=51.83, P < 0 001) (Figures 8(c) and
8(e)). These results suggest that while treatment did not
impact the number of labeled DPSNs, the AAV-KLF7 treat-
ment can effectively be transduced to DPSNs at the T7–T9
levels above the spinal cord lesion.
3.8. AAV-KLF7 Significantly Improves DPSN Plasticity
around the T10 Lesion Site 5 Weeks following SCI. The glial
fibrillary acidic protein- (GFAP-) immunoreactive astrocytes
and BDA-labeled DPSN axons and terminals were examined
around the spinal cord lesion site by immunofluorescence
staining (Figures 9(a) and 9(b)). The results showed no
difference in GFAP expression between the two groups
(SCI +AAV-KLF7, 66.31± 6.52; SCI +AAV-GFP, 65.14±
9.57; t10 = 0.234, P > 0 05) (Figure 9(c)); however, the
number of BDA-labeled DPSN axons and terminals
extended around the lesion through the spared white matter
was significantly increased in the SCI +AAV-KLF7 group
(39.95± 2.70) compared to the SCI +AAV-GFP group
(32.37± 1.25) (t10 = 4.964, P < 0 01) (Figure 9(d)). These
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Figure 8: AAV-KLF7 significantly infects DPSNs at T7 and T9 levels after SCI. Five weeks after contusion injury, (a-b) representative
immunohistochemical stainings for KLF7 (green) and FG (retrograde-labeled DPSNs, blue) in the Rexed lamina VII at the T7 and T9
levels are shown across the SCI +AAV-GFP and SCI +AAV-KLF7 groups. Cell counts were performed at the T7 and T9 levels with 15
sections per segment. Quantitative analyses of the KLF7 relative density (c), FG-labeled neurons (d), and percentage of FG/KLF7 double-
labeled neurons (e) above the lesion area. n = 6 mice/group. Student’s t-tests; green indicates SCI +AAV-GFP control; red indicates
SCI +AAV-KLF7. ∗∗∗P < 0 001. NS: not significant. Scale bars: 50μm.
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findings suggest that AAV-KLF7 treatment may promote
DPSN plasticity at the lesion site.
3.9. AAV-KLF7 Promotes DPSN Axonal Plasticity and
Synaptogenesis with Motor Neurons at the Caudal Spinal
Cord following SCI. Next, we performed immunohistochem-
ical staining of DPST axons and terminals using BDA labeling
in conjunction with retrograde CTB labeling of lumbarmotor
neurons and synaptic (SYP) protein detection at the caudal
spinal cord (Figure 10(a)). We found that the expression of
BDA and SYP was significantly decreased following SCI
compared to that of uninjured sham controls; moreover,
the expression of BDA and SYP per motoneuron in the
SCI +AAV-KLF7 group was significantly higher than that
in in the SCI +AAV-GFP group (BDA: SCI +AAV-KLF7,
1600± 74.28; SCI +AAV-GFP, 1238± 188.6; and sham,
3509± 342.0; F2, 15 = 197.8, P < 0 001; SYP per motoneuron:
SCI +AAV-KLF7, 218.3± 61.66; SCI +AAV-GFP, 137.9±
49.79; and sham, 326.6± 43.13; F2, 15 = 26.45, P < 0 001)
(Figures 10(c) and 10(d)). However, the number of CTB-
labeled motoneurons at the caudal spinal cord showed
no difference across the three groups (SCI +AAV-KLF7,
16.33± 1.633; SCI +AAV-GFP, 17.17± 1.941; and sham,
16.67± 1.633; F2, 15 = 0.348, P > 0 05) (Figure 10(b)). These
results demonstrated that KLF7 upregulation enhances
DPST plasticity at the caudal spinal cord following SCI.
3.10. AAV-KLF7 Promotes Axonal Myelination around the
Lesion Site following SCI. Electron microscopy showed that
the myelinated ratio of the uninjured sham group was higher
than that of the injured SCI +AAV-KLF7 and SCI+AAV-
GFP groups. Notably, the myelinated ratio in the SCI +
AAV-KLF7 group was significantly higher than that in
the SCI +AAV-GFP group (SCI+AAV-KLF7, 2.33± 0.438;
SCI +AAV-GFP, 1.48± 0.42; and sham, 3.26± 0.37; F2, 27 =
18.62, P < 0 001) (Figures 11(a), 11(b), 11(c), and 11(d)).
Though not totally in agreement, the results overall suggest
that SCI +AAV-KLF7 improves axonal myelination around
the lesion site.
3.11. KLF7 Expression in Oligodendrocyte Precursors after
AAV-KLF7 Treatment following SCI. To determine the
cellular localization of KLF7 expression after AAV-KLF7
treatment, the double-label immunohistochemistry for
KLF7 and CC1 (labeling oligodendrocytes), NG2 (labeling
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Figure 9: AAV-KLF7 significantly improves DPSN axonal plasticity around the lesion. Five weeks following contusion injury,
(a-b) representative immunohistochemical stainings for GFAP (green) and BDA (labeling DPSN axons, red) and nuclear staining (DAPI,
blue) surrounding the epicenter of SCI +AAV-GFP and SCI +AAV-KLF7 groups are presented. Quantitative analyses of the GFAP
relative density (c) and BDA relative density (d) around the lesion area. n = 6 mice/group. Student’s t-tests; green indicates SCI +AAV-
GFP control; red indicates SCI +AAV-KLF7. ∗∗P < 0 01. NS: not significant. Scale bars: 300μm or 100μm.
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oligodendrocyte precursors), and GFAP (labeling astrocytes)
was performed.
The majority of NG2-positive cells expressed KLF7;
the percentage of NG2/KLF7 neurons is 84.22± 6.95%
(Figure 12(a)). However, a few CC1-positive cells expressed
KLF7 (percentage of CC1/KLF7 neurons: 10.23± 2.39%)
(Figure 12(b)), and no astrocytes were found to express
KLF7 (Figure 12(c)). The results overall suggest that
overexpressed KLF7 in oligodendrocyte precursors cells
may promote axonal remyelination after SCI.
3.12. AAV-KLF7 Infection Does Not Affect Tibialis Anterior
Muscle Atrophy of Motor Endplate Density. To assess whether
AAV-KLF7 infection had any effect on TA muscle atrophy,
we assessed the muscle weight of TA and motor endplate
density across the three groups. Following SCI, TA muscle
weight is decreased by 34.42% as compared to that of
the uninjured sham group; however, no difference was found
in TA muscle weight between the SCI +AAV-KLF7 and
SCI+AAV-GFP groups (SCI +AAV-KLF7, 0.041± 0.007 g;
SCI +AAV-GFP, 0.040± 0.006 g; t12 = 0.299, P > 0 05)
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Figure 10: AAV-KLF7 promotes DPSN axonal plasticity and induced synapse formation with motor neurons at the caudal spinal cord.
(a) Contact between motoneurons (CTB retrogradely labeled, red) and DPSN axons (BDA-labeled, green) and synapse formation
(synaptophysin-labeled, purple) are shown. Block indicates the new synapses formation (white) between DPSN axons and
motoneurons. Quantitative analyses of the motor neuron targeted CTB-labeled axons (b), BDA relative density (c), and SYP density
per motoneuron per section (d) at the caudal spinal cord. n = 6 mice/group. ∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001. NS: not significant.
One-way ANOVA, Tukey’s post hoc test. Scale bars: 100 μm.
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(Figure 13(b)). In addition, motor endplate staining showed
no difference in the number of endplates per muscle fiber
across either of the three groups (SCI +AAV-KLF7, 0.486±
0.225; SCI +AAV-GFP, 0.582± 0.232; and sham, 0.515±
0.251; F2, 15 = 0.262, P > 0 05) (Figures 13(a) and 13(c)).
3.13. KLF7 Transfection Significantly Enhances Motor
Functional Recovery following SCI. BMS behavioral scores
are represented in Figure 13(a); the results showed that
BMS scores were significantly increased in the SCI
+AAV-KLF7 group (6.93± 0.41) compared with the SCI
+AAV-GFP group (6.06± 0.77) 5 weeks after injury (F2,
21 = 59.88, P < 0 001) (Figure 14(a)). In a similar vein, grid
walk locomotor analysis showed that the number of foot
drops during grid walking was significantly improved by
AAV-KLF7 treatment (9.75± 1.48) compared to the
AAV-GFP treatment (11.75±1.48) (F2, 21=104.2, P < 0 001)
(Figure 14(b)).
Finally, we measured electrophysiological characteristics
of descending axons in the ventral spinal cord to assess
functional recovery across the three groups (Figure 14(c)).
The SCI +AAV-KLF7 (4.76± 0.44) and SCI+AAV-GFP
groups (2.33± 0.28) displayed decreased wavelength ampli-
tude compared to the uninjured sham group (19.17± 2.63)
(F2, 21 = 205.7, P < 0 001) (Figure 14(d)); however, the SCI
+AAV-KLF7 group displayed a significant improvement
over the SCI +AAV-GFP group. Wavelength latency was
increased in the injury groups compared to sham (SCI +
AAV-KLF7, 1.38± 0.15; SCI+AAV-GFP, 1.70± 0.10; and
sham, 1.11± 0.11; F2, 21 = 31.73, P < 0 001) (Figure 14(e))
though SCI+AAV-KLF7 significantly reduced this injury-
induced latency. Overall, the SCI +AAV-KLF7 treatment
showed a better electrophysiological response compared to
the SCI +AAV-GFP treatment and supports a functionally
relevant therapeutic impact of KLF7 overexpression.
4. Discussion
SCI induces a biphasic sequence whereby inhibitory factors
targeting injured neurons and hindering recovery are
followed by intrinsic repair elements such as sprouting and
axonal plasticity. As investigators continue to unravel the
complexities of the injury response, both inhibitory factors
and endogenous repair targets have been exploited in
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Figure 11: AAV-KLF7 promotes axon myelination around the lesion. Transmission electron microscope (TEM) analysis was used to assess
remyelination of spinal axons across the sham (a), SCI +AAV-GFP (b), and SCI +AAV-KLF7 groups (c) (n = 10). Quantitative analyses of
the myelinated ratio (d). ∗P < 0 05, ∗∗∗P < 0 001, one-way ANOVA, Tukey’s post hoc test. Bar indicates 1 μm.
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preclinical models to optimize recovery. For example, high-
throughput screening of inhibitory targets has revealed
PTEN and Sac2 as inhibitors of axon plasticity in mouse
cortical neurons [35], the first important step toward
minimizing their influence postinjury. Conversely, a variety
of targets implicated in endogenous repair mechanisms have
been the source of manipulation studies, highlighting a com-
plimentary approach to the optimization of post-SCI repair.
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Figure 12: Cellular localization of KLF7 expression in the mouse spinal cord after spinal cord injury (SCI). (a) Little KLF7 immunoreactivity
(IR) was localized in oligodendrocytes indicated by CC1 IR (arrows). (b) KLF7 immunoreactivity (IR) was localized in oligodendrocyte
precursors indicated by NG2 IR (arrows). (c) No KLF7 immunoreactivity (IR) was localized in astrocytes indicated by GFAP IR (arrows).
Scale bars: 100 μm.
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Figure 13:Weight of TAmuscle and the number of motor endplate are unaffected by KLF7 following SCI. (a) Acetylcholinesterase staining in
sham, SCI +AAV-GFP, and SCI +AAV-KLF7 groups. Quantitative analyses of TA muscle weight (b) and the numbers of endplate per
fiber (c) (n = 6 mice/group). Error bars show SD. ∗P < 0 05, ∗∗P < 0 01, one-way ANOVA, Tukey’s post hoc test. NS: not significant.
Scale bars: 50μm.
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Due to the multifaceted nature of axonal plasticity,
remyelination, and synapse formation (critical components
of injury repair), targeting single genes for optimization is
likely to yield limited improvements. Instead, many investi-
gators have looked toward regulators of gene networks such
as transcription factors of various regeneration-associated
pathways. Here, we expanded upon previous reports of
improved axonal regeneration and functional recovery
attributed to the regulatory factor KLF7 established in the
injured CST [10, 12, 36]. The goal of this study was to deter-
mine whether KLF7 treatment could be a novel strategy for
DPSN axonal plasticity and functional repair after SCI.
Here, we confirm the effectiveness of KLF7 upregulation
as a therapeutic strategy in descending propriospinal axon
plasticity following contusive SCI. The plasticity and regener-
ative capacity of which are likely essential to transmission of
supraspinal motor command and thereby an important
factor for functional motor recovery [19].
Foremost, this study set out to characterize the effective-
ness of AAV-driven upregulation of endogenous KLF7 and
its downstream targets in vitro. We report that spinal cord
neuron transfection was efficient and significantly upregu-
lated the target elements. Particularly, KLF7 induction
increased the expression of the neurotrophic factor NGF
and its receptor TrkA, elements previously implicated in
axon development and regeneration after injury, mainly
through MAPK-ERK1/2 and PI3K pathways [37]. As pre-
dicted, the advent of upregulated KLF7 and NGF/TrkA was
supported by increased neurite outgrowth observed in both
spinal neurons and DRG explants. These results are in
agreement with previous reports of KLF7 upregulation and
axon growth in culture [38] and compliment earlier findings
that KLF7 disruption is associated with deficits in neurite
outgrowth and axonal misprojection [39].
After confirmation of AAV-KLF7 efficiency in vitro, we
next applied the upregulation strategy in a live model of
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Figure 14: AAV-KLF7 significantly enhanced motor functional recovery following SCI. (a) Quantitative analyses of the Basso Mouse Scale
(BMS) locomotor scores post-SCI (b), number of foot drops during grid walking five weeks postinjury (c), and tcMMEP responses five weeks
postinjury (d), including the amplitude (mV) (e) and latency period (ms) from each group (n = 8), are shown. Error bars denote SD.
∗P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001, one-way ANOVA, Tukey’s post hoc test.
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contusive T10 SCI. In vivo, the AAV-KLF7 construct was suf-
ficient to drive KLF7 overexpression up to 5 weeks postin-
jury, prolonging the endogenous elevation of KLF7 by 1-2
weeks compared to the intrinsic injury profile. As observed
in culture, several KLF7 targets and injury-related proteins
were maintained in an elevated state 5 weeks after injury.
Particularly NGF, the NGF receptor TrkA, and GAP43 all
demonstrated some intrinsic, injury-related elevation which
was enhanced significantly by AAV-KLF7. As noted earlier,
the NGF/TrkA signaling cascade plays a role in axon regen-
eration after injury. Similarly, the growth-associated protein
43 (GAP43) has demonstrated importance in axonal rege-
neration [40], containing regeneration-specific proneural
enhancer regions in fish homologs [41]. Complimentary to
these observations, the injury-related response of the myelin
protein P0 was significantly mitigated by AAV-KLF7 treat-
ment. While injury induces a drastic drop in P0 abundance,
likely representing demyelination and degeneration, AAV-
KLF7 treatment demonstrated significant elevation of the
protein compared to AAV-GFP treatment. Considering
myelination assessments conducted via electron microscopy
(further detailed below), there was corroborating evidence
that KLF7 overexpression plays a role in myelin preservation
and/or axon remyelination. Interestingly, closer assessment
of KLF7-upregulating cells revealed that the majority of
KLF7 upregulation was displayed by oligodendrocyte precur-
sors (NG2+ cells). This appears to complement earlier reports
that KLF6 plays a critical role in oligodendrocyte differentia-
tion [42]and further substantiates the role of KFL7 in myelin
preservation and remyelination after SCI.
Importantly, in vivo, pathological assessment revealed
that KLF7 overexpression was not sufficient to influence
the lesion area or volume; however, the treatment did sig-
nificantly improve the amount of myelin sparing following
contusive SCI. These findings echo a previous study in
which combined KLF7 overexpression and chondroitinase
were not sufficient to circumvent the lesion size [12].
Despite this restriction, myelin sparring is significant and
has been correlated with improved oligodendrocyte survival
and improvements in motor function in human spinal cord
injury [43].
Wang et al. recently discuss that KLF7 upregulation may
bear differential effects based on the cell type and injury
model [12]. In this vein, it was important for our group to
examine a population of neurons that has been previously
highlighted in the preservation and recovery of motor func-
tion during SCI. The anatomical positioning and projection
patterns of propriospinal neurons have made them the sub-
ject of an intense study in SCI. Proposed to be involved in
the regulation of locomotion, limb coordination, and pos-
tural support, propriospinal neurons may even possess the
capacity to circumvent denervation by relaying supraspinal
motor commands to the lumbar spinal cord after thoracic
injury [44]. Additionally, descending propriospinal neurons
(DPSNs) in the ventral motor area could directly innervate
motor neurons of hind limb muscles and in turn may
be innervated by injury-mediated supraspinal sprouting,
collectively positioning the neuron pool as a major role
player in functional recovery following SCI [45]. Indeed,
some apparently inherent features of propriospinal neurons
compared to supraspinal counterparts reveal an enhanced
resilience and injury-repair response in the form of sparring
and sprouting [46, 47]. An important neuroprotective prop-
erty of surviving propriospinal neurons which project past
the lesion site is their ability to form a “bridge” between
regenerated descending signals and their targets past the
lesion [48]. These properties (coincidental with enhanced
responsiveness to SCI therapeutic strategies [17]) suggest
perhaps a more viable therapeutic approach toward recovery
of motor function in SCI.
Examination of DPSN projections via retrograde label-
ing revealed that L2-projecting DPSNs were sensitive to
KLF7 treatment, displaying increased expression of the
transcription factor. This finding likely indicates that
AAV-KLF7 is effective at targeting DPSNs in vivo and
likely exerting its putative functions in that neuron pool,
including neurotrophic factors and axonal growth cues as
discussed above. Similarly, anterograde tracing via BDA
labeling demonstrated that DPSN axons are increasingly
extended around the lesion through the spared white matter
in KLF7-treated groups. Taken together, increased presence
of BDA-labeled DPSN tracts and increased SYN expression
of motor neuron targets in the caudal spinal cord indicate
plasticity and sprouting of spared axons and importantly
suggest meaningful contributions to functional recovery.
One discrepancy we found was the absence of injury or
treatment effect in the number of retrogradely labeled neu-
rons compared to the anterogradely labeled neurons. We
suggest that this may be due to the fact that cell bodies
of short propriospinal neurons above the lesion are rela-
tively resistant to retrograde death and apoptosis after
axotomy [49]. At present, there is no evidence that KLF7
overexpression promotes spinal cord neuron survival or
inhibits cell apoptosis in vitro. However, in vitro, KLF7
overexpression promotes neurite outgrowth of spinal cord
neurons and DRG explants. Therefore, in vivo, the action
of KLF7 may occur at the cell soma or axon of these
DPSNs to promote their axonal spouting across the SCI
lesion but is perhaps not a major contributor to labeled
DPSN cell survival or apoptosis. As such, further investi-
gation is needed to reveal the effect and mechanism of
KLF7 overexpression on neuron survival.
Examination of motor neurons and target muscle tissues
identified that KLF7 treatment did not impact the number of
motor neuron innervations of the sciatic nerve (identified by
CTB labeling in the lumbar spinal cord), nor did it affect
motor endplate densities or anterior tibial muscle weight.
The apparent insensitivity of the lumbar motor neurons
and target muscles likely reflects their distance from the
T10 contusion injury site. Despite this, KLF7 treatment did
impact functional outcomes as reported by behavioral and
locomotor examination 5 weeks after injury. The reconcil-
iation of improved motor capacity and restricted axonal
plasticity observed at motor targets may support the previ-
ously described notion that functional recovery in SCI may
be mediated by DPSN axonal bridging at the lesion site,
communicating supraspinal motor commands to motor
neurons. This argument is strengthened by the observed
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increase in synaptogenesismarkers, the enhancedmyelination
of existing axons, and the improved conductivity of the DPSN
axons of the ventral spinal cord. Effectively, AAV-KLF7
treatment after SCI appears to strengthen the regenerative
and functional capacity of DPSNs through spared tissue,
likely contributing to improved behavioral outcomes. This
is significant particularly because previous reports have
rejected the notion that KLF7 manipulation could indepen-
dently contribute to functional recovery after SCI [12].
These results provide evidence that actively engaging
KLF7 improves function and that one likely mechanism
may be the upregulation of KLF7 in oligodendrocyte precur-
sors and subsequent differentiation which may promote
myelin sparring and/or remyelination which plays a critical
role in functional recovery after SCI. Myelination of axons
is a prerequisite for the rapid propagation of nerve impulses.
To obtain adequate functional recovery, regenerated axons
must be myelinated. Previous studies have confirmed that
surviving oligodendrocyte precursors are the major source
for oligodendrocyte (OL) replacement and remyelination
after SCI [50]. Additionally, a recent study has confirmed
the critical nature of the KLF7-relative KLF6 in the differen-
tiation of oligodendrocyte precursors in the adult CNS [42].
Here, we propose that overexpression of KLF7 in oligoden-
drocyte precursors promotes OL replacement and meaning-
fully contributes to enhanced DPSN remyelination after
SCI, promoting DPSN axonal plasticity and myelination
and consequently promoting functional recovery. However,
the conclusive evidence of this mechanism requires the
design of a sequence of new experiments which is beyond
the scope of the current study.
Another likely mechanism underlying the functional
contributions of KLF7 upregulation is the reorganization
and reengagement of rostrocaudal spinal interneuronal
networks. Functionally, the propriospinal intersegmental
linkage can mediate and/or facilitate motor coordination, as
observed by several studies which have demonstrated that
spared spinal pathways undergo extensive reorganization to
increase recruitment of propriospinal pathways for motor
recovery. Additionally, the short propriospinal neurons
primarily located in T7–T9 which innervate lumbar motor
neuronal pools may relay signals from the long supraspinal
descending systems to the motor neurons in the lumbar cord,
creating new functional circuits around an incomplete lesion
and providing the substrate for locomotor recovery [49]. We
believe that the rostrocaudal interneuronal networks are
reengaged after KLF7 treatment to enhance locomotor recov-
ery. This proposition is supported by greater axonal plasticity
of propriospinal interneurons bilaterally at and below the
level of the lesion site denoting enhanced contact of lumbar
neuronal networks.
An important study by Siebert et al. recently examined
the time-dependent gene expression changes in thoracic
PNs following SCI. Three days after SCI (a complete tran-
section at T9), thoracic PNs showed an upregulated expres-
sion of a suite of regeneration-associated genes (including
Actb, Atf3, Cd44, Crem, Ctsb, Gap43, Hsbp1, Jun, Pacap,
Sox11, Stat3, and Tubb3). Some of these genes play impor-
tant roles in the production of injury-associated mRNA
transcripts, while others can affect processes such as growth
cone dynamics [51, 52]. In our study, AAV-KLF7 treat-
ments exerted their plastic/regenerative effects by acting
on the DPSN body. Thoracic DPSN showed an upregulated
expression of KLF7, an important regulator of growth fac-
tors such as NGF and TrkA which promote sprouting and
axon regeneration, a key feature of path finding and new
synapse formation. Evidence of this interaction can be
deduced from the enhanced neurite outgrowth which was
observed in response to KLF7 in vitro and via axon plastic-
ity in DPSN populations with a sustained effect. DPSN
sprouting in turn may facilitate functional recovery via
one of its many structural and physiological intersections
with motor signaling and command.
Despite the wealth of knowledge on manipulations that
enhance DPSN axonal sprouting and consequent motor
functional recovery, the intrinsic mechanisms underlying
recovery have not yet been fully elucidated. Further inves-
tigation is needed to reveal the broader mechanisms of
these changes in plasticity and how they recognize specific
partners to form synapses. Understanding the underlying
molecular mechanisms may be helpful in establishing
new therapeutic methods for the recovery of impaired
function. Here, the proposed involvement of KLF7 and
downstream growth factors may provide more insight
than has previously been put forth. Our observed KLF7
upregulation falls in line with previous findings which
reported the time-dependent gene expression changes in
thoracic PNs following SCI. For example, after SCI, tho-
racic PNs showed an upregulated expression of a suite of
regeneration-associated genes; some of which play impor-
tant roles in the production of injury-associated mRNA
transcripts, while others can affect processes such as
growth cone dynamics [51, 52]. For example, Gap43
expression in neurons has been correlated with axonal out-
growth, path finding, and new synapse formation via inter-
actions with extrinsic signaling molecules (such as
neurotrophic factors and cell adhesion proteins) and
intrinsic cytoskeletal elements including actin [53, 54].
KLF7, in a similar vein, may underlie neurophysiological
and functional recovery.
Another important consideration is the assumption that
increased KLF7-mediated growth signaling is exclusively a
beneficial parameter. The reality is that growth factor signal-
ing is a multifaceted business and, though typically seen as
therapeutic in neurodegeneration, cannot be conclusively
accepted as unilaterally beneficial without rigorous testing.
Grounds for the presumed therapeutic nature of growth
factors come from the existence of neurotrophic factors as
concentration gradients directing axonal growth toward their
targets. However, growth factor concentration may also
influence misguidance of axonal targets and negatively
impact functional neurocircuitry [55]. Similarly, some
growth factors, including the KLF7-mediated Trk receptors,
have shown antagonizing action on cell survival in certain
contexts [56, 57]. Considering the growing complexity of
ligands, associated factors, and signaling cascades, it would
not be surprising if additional layers of interactions impinge
upon the overall contributions of the growth cues. As such,
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future studies will have to tease out the contributions of
enhanced growth and neurotrophic factors in the context of
cell type, spatial and temporal patterning, and interaction
with the insult [58, 59].
5. Conclusion
The intrinsic regulatory capacity of KLF7 in axonal growth and
synaptogenesis can be manipulated to overcome injury-related
restrictions in a model of T10 contusive SCI. Likely operating
under a variety of neurotrophic, survival, and myelinogenesis
pathways, we have identified a novel population of KLF7-
responsive spinal cord neurons. Here, we characterized the
extent of KLF7-driven enhancements and limitations on the
DPSN axons, outlining axonal plasticity, synapse forma-
tion, and functional parameters which are likely account-
able for observed functional recovery. We conclude that
KLF7 overexpression is stable and functional and targets
a population of spinal neurons heavily implicated in motor
regulation. These DPSNs respond in kind by strengthening
their functional capacity postinjury, likely contributing to
overall improved behavior. In closing, this study supports
the optimization of the intrinsic injury response as an
effective therapeutic strategy for SCI treatment. And while
other targets and strategies continue to be elucidated,
investigators will be able to develop improved combinato-
rial strategies to target the multiple deficits and enhance
the multiple repair signals of the SCI response, bringing
the field ever closer to optimal SCI recovery.
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